LAT, linker for activation of T cells
The control group of rats was not given the BPC-157 peptide
FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.18 In other words, there have been no dedicated safety studies on KPV, so its status as a safe or unsafe therapy is up in the air
HPLC may provide peptide-purity information, while the arginine-associated component may require separate analysis
Product documentation generally includes peptide content, CAS number, molecular formula, molecular weight, and confirmation of analytical testing, supporting batchtobatch reproducibility for laboratory protocols